

Yoghurt (LAB) as preventive method against COVID-19

BOSE KARTHIK YATHATI^{1,2*}¹Indian Institute of Technology, Madras - Biomedical, (IIT-M),
IIT Madras, INDIA²Indian Institute of Technology, Bhubaneswar, (IIT-BBSR),
Odisha, INDIA***Correspondence author****Bose Karthik,**
IIT Madras,
IIT Bhubaneswar
India
Orcid ID: 0000-0003-1992-461X

Submitted : 11 Apr 2023; Published : 29 Apr 2023

Citation: Karthik B.(2023). Yoghurt (LAB) as preventive method against COVID-19. J Medical Case Repo, 5(1):1-9.
DOI : <https://doi.org/10.47485/2767-5416.1031>**Introduction**

SARS-COV-2 explores every possible vulnerability in human body and uses it against the host. To treat this SARS-COV-2 induced COVID-19, we should consider and target the multiple factors this virus is targeting and identify the drugs for usage in a strategical way. This approach can save the patients from severe state of illness and damage associated with this disease. COVID-19 has been associated with hyper inflammation [101-109] and delayed humoral immune responses [110-115]. Most of the complications with COVID-19 patients have been associated with early hypoxia, ARDS, pneumonia [116-122] and Acute Lung Injury [123-127]. Viral load has been found to be associated directly with incidence of lung injury/epithelial injury or remote organ injury in COVID-19 patients [128-133].

Conclusively, SARS-COV-2 is reported to be associated with severe immune dysregulation, delayed humoral responses and accelerated innate immune response mediated damages. As the pandemic is turning the world upside down, In order to address this disease we should first get an insight into the mechanism of action through which SARS-COV-2 is achieving the above said dysregulating or modulating effects on human immune system.

SARS-COV-2 dysregulates immune system by targeting innate immune system, adaptive immune system and different immune tolerance check points by dysregulating different miRNA's and the preexisting conditions or comorbidities of the patients.

This article targets the data available/ reported till date in the scientific community and tries to provide comprehensive review/insights into the beneficial usage of Probiotics (not all Probiotics)

/Tyndallized Probiotics especially Yoghurt in preventing COVID-19 during very initial/early stages but not during the treatment of the disease.

Importance of Microbiota for Respiratory Viral Immunity

Yoghurt consumption is good for enhancing the respiratory immune system [51,52]. Shi et.al conducted an analysis of 58 studies (9 randomized controlled trials; 49 animal studies)

and reported that six of the eight clinical trials consisting of 726 patients show the importance of probiotics administration in reducing the risk of damage during respiratory tract viral infections (RTIs) [94].

Most commonly used probiotics were reported to be Lactobacillus followed by Bifidobacterium and Lactococcus [94]. Shi et.al concluded that in animal models, treatment with probiotics before viral challenge have beneficial effects against influenza virus infection by improving infection-induced survival (20/22 studies), mitigating symptoms (21/21 studies) and decreasing viral load (23/25 studies) [94]. Probiotics and commensal gut microbiota exerts their beneficial effects by strengthening the host immune system [94].

Bradley et.al reported that Microbiota can stimulate Interferon Signaling in Lung Stromal Cells that Protects from Influenza Virus Infection [99]. LAB (Lactic Acid Bacteria) can stimulate and induce the release of Interferon (IFN) [86,87,90,99] and IL-10 [88,92-95].

Probiotics can help in preventing and addressing viral exacerbations [62] and Lung Infection problems [61,65]. Eguchi et.al showed that respiratory syncytial virus (RSV) infection can be prevented with

probiotic lactic acid bacterium Lactobacillus gasseri SBT2055 [63]. In the experiment conducted by Eguchi et.al the expression level of the proinflammatory cytokines TNF- α , CCL2, IL-1 β except IL-6 were reported to be reduced after 4 days in Probiotic treated mice [63].

Silvia et.al demonstrated that the administration of Lactobacillus casei CRL 431 or Lactococcus lactis NZ9000 were able to increase S. pneumoniae clearance rates in lung and blood [51], improved survival of infected mice and reduced lung injuries [60,3].

It has been demonstrated that gut-associated lymphoid tissue is stimulated by L. bulgaricus CRL 423 and S. thermophilus CRL 412, resulting in the enhanced production of cytokines

and secretory IgA [4,5]. Perdigon et.al showed that LAB has the ability to stimulate the production of IgA [7]. Galdeano et.al showed that the Probiotic Bacterium *Lactobacillus casei* Induces the activation of the Gut Mucosal Immune System through Innate Immunity and adaptive immune system [57]. Probiotics play important role in stimulating adaptive immune system related IgA responses at the mucosal surfaces required by respiratory immune system for protection against respiratory viral infections [67,57,51].

Probiotic treatment could effectively inhibits LPS-induced autophagy in intestine epithelial cells [11]. Specific probiotic strains could decrease colonic LPS thus it's leakage into systemic blood, systemic inflammation and associated potential damage [12,13]. LAB can protect against inflammation in several cases [24,12,13,14,15,16,17,18]. Moludi et.al through their trial revealed that 12 weeks' probiotic supplementation (*L. rhamnose*) has a positive effect on endotoxemia and chronic inflammation in CAD (coronary artery disease) patients [14]. LAB is reported to be good for reducing the symptoms of upper respiratory tract during respiratory viral infections in overweight and obese adults [53]. Taken together LAB might be good for preventing co-morbid situations in people in some cases. LAB is good for addressing antibiotic associated side effects [22].

Microbiota might modulate Inflammasome

Although intestinal flora are crucial in maintaining immune homeostasis of the intestine, the role of intestinal flora in immune responses at other mucosal surfaces remains less clear [95].

Wu et.al showed that TLR-7 ligands rescue the immune impairment in an antibiotic-treated mice during IAV infection [95]. This is in agreement with other studies by Kelly et.al which reported that antibiotics dysregulate gut microbiota and downregulate TLR-7 expression at the other mucosal surfaces independent of the delivery Route i.e: either administered through oral or Intravenous ways [96]. Animal studies have also proved the adverse influence of antibiotics in viral Respiratory Tract Infections (RTIs) [97,98,99].

Conclusively, Wu et.al reported that good intestinal flora composition is critical in sustaining and regulating the toll-like receptor 7 (TLR-7) expression and signalling pathways during respiratory influenza virus infection [95].

Intact microbiota provides signalling leading to the expression of mRNA for TLR-7, MyD88, IRAK4, TRAF6, and NF- κ B at steady state [95]. Significant changes in the composition of culturable commensal bacteria reduce the expression levels of components of the TLR-7 signaling pathway [95].

Ichinohe et.al also showed that commensal microbiota composition critically regulates the generation of virus specific CD4+ and CD8+ T cells and antibody responses following respiratory influenza virus infection [100].

Jeisy et.al showed that in the absence of effective TLR-7 signalling during damage induced by IAV infection, the M-MDSCs get accumulated to the infected site in Lungs rapidly, resulting in the suppression of Virus specific T cell (ex: CD8+ T cell) and other immune responses [101].

Yukong et.al observed that Influenza infection lead towards an increase in the proportions of Th1/Th2 and Th17/Treg cells in the infected group suggesting that influenza virus promotes inflammation mediated damage via Th1 and Th17 cells [102].

Yukong et.al observed that TLR-7 expression was upregulated in mice when infected with higher viral load of Influenza virus (IAV) infection than compared to normal uninfected control mice [102]. This upregulation of TLR-7 is reported to be associated with promoting inflammation and useful in controlling viral burden [102]. Although TLR-7 expression upregulation during inflammation further promotes inflammation, it is reported to be essential to sense and control the viral burden since TLR-7^{-/-} mice is found to be subjected with faster viral growth and subsequent higher mortality rate [102]. Yukong et.al observed that increased viral load is associated with more damage due to monocyte and other inflammation mediated damage [102].

This is in agreement with other observations which states that TLR-7 reduction during acute phase of inflammatory response due to viral infection might lead to subsequent increase in viral load and subsequent damage induced by monocytes as seen in IAV [103,104,105,106].

Jeisy et.al showed that TLR-7^{-/-} mice during IAV infection is associated with higher titers of viral burden in Lungs and subsequent higher mortality rate [101]. Jeisy et.al also reported that TLR-7 has important role during secondary stage of viral infection (IAV) through sensing the viral RNA and limiting viral growth through inflammation but not during earlier stages of the infection [101].

Wu et.al revealed the importance of intestinal flora in regulating immunity in the respiratory mucosa through the upregulation of the TLR-7 signaling pathway for the proper activation of inflammasomes [95]. Ichinohe et.al reported that local or distal injection of Toll-like receptor (TLR) ligands could rescue the immune impairment in the antibiotic-treated mice [100]. Intact microbiota provides signals leading to the expression of mRNA for pro-IL-1 β and pro-IL-18 at steady state. During influenza virus infection, inflammasome activation helps in migration of dendritic cells (DCs) from the lung to the draining lymph node and T-cell priming [100]. Ichinohe et.al results revealed the importance of commensal microbiota in regulating immunity in the respiratory mucosa through the proper activation of Inflammasomes [100].

Gut Microbiota and Tregs relation

It is now well established that resident microbes provide enormous advantages to the host, while dysbiosis can trigger acute and chronic inflammatory conditions [107]. One of the mechanisms by which these microbes regulate immunity is

through controlling Tregs and Th-17 cells balance [107]. Taken together microbiota is essential for proper TLR-7 expression and signalling pathways along with proper activation of Inflammasomes [107].

Impaired Inflammasome in COVID-19

Impaired Inflammasome activity observed in severe COVID-19 patients [108-112].

Microbiota dysregulations observed in COVID-19 patients and related Trials

Gut microbial dysbiosis has been identified in COVID-19 patients, characterized by the enrichment of opportunistic pathogens and depletion of beneficial commensals [113,114,115]. Gut microbiota alterations are reported to be associated with disease severity. Zuo et.al reported that the severity of COVID-19 is positively correlated with the baseline abundance of Coprobacillus, Clostridium ramosum, and Clostridium hathewayi, and inversely correlated with that of Faecalibacterium prausnitzii (an anti-inflammatory bacterium) [113]. Subjects with gut dysbiosis, such as elderly, immunocompromised patients and patients with other co-morbidities are reported to have more severe disease and poorer outcomes of COVID-19 [116].

However, not all probiotics are equivalent for efficacy [117]. A novel and more targeted approach to modulate gut microbiota as one of the therapeutic strategies for COVID-19 and its complications is much needed. In a recent study reported by d'Ettorre et al., among COVID-19 patients, oral

administration of a probiotic mixture significantly reduced the risk of developing respiratory failure, and a trend towards reduced rates of mortality [118].

It has been reported that Chinese University of Hong Kong team has developed an oral gut microbiota modulating formulation against COVID-19. In a pilot study, this formulation significantly improved clinical symptoms and reduced pro-inflammatory immune markers in COVID-19 patients [119].

Probiotics rescue from Antibiotic Abuse

Viral infections predispose patients to secondary bacterial infections, which often result in a more severe clinical course [120]. Empirical antibiotics are sometimes used for the management of viral infection when secondary bacterial infection is a concern. However, Zuo et al. revealed that antibiotics use led to further loss of salutary symbionts and exacerbation of gut dysbiosis in COVID-19 patients [113] which is in confirmation with other authors [95,96]. Animal studies have also proved the adverse influence of antibiotics in viral RTIs [97,98,99]. These results suggest clinicians to avoid unnecessary antibiotics use in the treatment of viral RTIs.

Antibiotics are known for dysregulating gut microbiota [113] and gut microbiota is related to TLR-7 expression at mucosal surfaces [95] and reduction in TLR-7 is associated with higher mortality in COVID-19 patients[121]. Microbiota regulates

the TLR-7 expression at mucosal surfaces which is helpful during viral infections [95,100,122].

Conclusively, early administration of LAB is beneficial to enhance viral immunity. LAB helps in enhancing Treg response, produce early interferon response, stimulate innate response and stimulate adaptive response by inducing IgA responses. Studies show that Lactobacillus protected against several respiratory virus in mice including IAV [123,122,124,125-128].

It has been revealed that intestinal flora is important in regulating immunity in the respiratory mucosa through the upregulation of the TLR7 signaling pathway for the proper activation of inflammasomes [95]. It has also been revealed that the commensal microbiota is important in regulating immunity the respiratory mucosa through the proper activation of inflammasomes [100].

Disadvantage of Probiotic Usage

1. Although LAB is good for many conditions [19,20,21,24,25,26,28,29], it should be taken care that at-risk, Immunocompromised and immunosuppressed people in all ages (ex: HIV, Cancer, Gut diseases, ill ICU patients, critically sick infants, frail elderly subjects, postoperative, hospitalized patients and patients with immune compromised complexity etc...) should avoid taking LAB as it might harm them as a secondary infection [82,58,59,77,78,80,81,23,27].
2. People should get the advice/recommendation to consume LAB or not by consulting with their concerned family physician/doctor who might check the patient's previous health conditions and recommend based on them.

Alternative Solution

Heat-Killed/(Tyndallized) Probiotics might be a solutions for this problem as observed in many other conditions. Chen et.al showed that pretreatment with a heat-killed E. faecalis probiotic can modulate the Monocyte Chemoattractant Protein-1 (MCP-1) and protect from/reduces the pathogenicity of two unrelated viruses influenza virus and enterovirus 71 (EV71) infections in mice [85].

Piqué et.al reported that their reviewed data indicate that heat-killed bacteria or their fractions or purified components have key probiotic effects, with advantages versus live probiotics (mainly their safety profile) [83,84].

Conclusion

Conclusively, Probiotics might be helpful as a preventive measure [64,66,89,91] but not during the treatment of COVID-19 disease.

References

1. Castro-Herrera VM, Rasmussen C, Wellejus A, Miles EA, Calder PC. In Vitro Effects of Live and Heat-Inactivated *Bifidobacterium animalis* Subsp. *Lactis*, BB-12 and *Lactobacillus rhamnosus* GG on Caco-2 Cells. *Nutrients*. 2020 Jun 8;12(6):1719. doi: 10.3390/nu12061719. PMID: 32521765; PMCID: PMC7352502.
2. Villena J, Racedo S, Agüero G, Alvarez S. Yoghurt accelerates the recovery of defence mechanisms against *Streptococcus pneumoniae* in protein-malnourished mice. *Br J Nutr*. 2006 Mar;95(3):591-602. DOI: 10.1079/bjn20051663. PMID: 16512946.
3. Villena J, Medina M, Vintiñi E, Alvarez S. Stimulation of respiratory immunity by oral administration of *Lactococcus lactis*. *Can J Microbiol*. 2008 Aug;54(8):630-8. DOI: 10.1139/w08-052. PMID: 18772925.
4. Dogi CA, Galdeano CM, Perdigón G. Gut immune stimulation by non pathogenic Gram(+) and Gram(-) bacteria. Comparison with a probiotic strain. *Cytokine*. 2008 Mar;41(3):223-31. DOI: 10.1016/j.cyto.2007.11.014. Epub 2008 Jan 8. PMID: 18248820.
5. Perdigón G, Vintiñi E, Alvarez S, Medina M, Medici M. Study of the possible mechanisms involved in the mucosal immune system activation by lactic acid bacteria. *J Dairy Sci*. 1999 Jun;82(6):1108-14. DOI: 10.3168/jds.S0022-0302(99)75333-6. PMID: 10386296.
6. Galdeano CM, de Moreno de LeBlanc A, Vinderola G, Bonet ME, Perdigón G. Proposed model: mechanisms of immunomodulation induced by probiotic bacteria. *Clin Vaccine Immunol*. 2007 May;14(5):485-92. DOI: 10.1128/CVI.00406-06. Epub 2007 Mar 14. PMID: 17360855; PMCID: PMC1865623.
7. Perdigon G, Alvarez S, Medina M, Vintiñi E, Roux E. Influence of the oral administration of lactic acid bacteria on iga producing cells associated to bronchus. *Int J Immunopathol Pharmacol*. 1999 May-Aug;12(2):97-102. PMID: 12783652.
8. Guarner F, Perdigon G, Corthier G, Salminen S, Koletzko B, Morelli L. Should yoghurt cultures be considered probiotic? *Br J Nutr*. 2005 Jun;93(6):783-6. DOI: 10.1079/bjn20051428. PMID: 16022746.
9. Alvarez S, Herrero C, Bru E, Perdigon G. Effect of *Lactobacillus casei* and yogurt administration on prevention of *Pseudomonas aeruginosa* infection in young mice. *J Food Prot*. 2001 Nov;64(11):1768-74. DOI: 10.4315/0362-028x-64.11.1768. PMID: 11726157.
10. Adnan, M. L., & Pramaningtyas, M. D. (2020). Probiotics as Promising Immunomodulatory Agents to Prevent COVID-19 Infection: A Narrative Review. *International Journal of Medical Students*, 8(2), 121–125. DOI : <https://doi.org/10.5195/ijms.2020.486>
11. Han C, Ding Z, Shi H, Qian W, Hou X, Lin R. The Role of Probiotics in Lipopolysaccharide-Induced Autophagy in Intestinal Epithelial Cells. *Cell Physiol Biochem*. 2016;38(6):2464-78. DOI: 10.1159/000445597. Epub 2016 Jun 17. PMID: 27309845.
12. Monteros, M.J.M., Galdeano, C.M., Balcells, M.F. et al. Probiotic lactobacilli as a promising strategy to ameliorate disorders associated with intestinal inflammation induced by a non-steroidal anti-inflammatory drug. *Sci Rep* 11, 571 (2021). <https://doi.org/10.1038/s41598-020-80482-z>
13. Rodes L, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C, Shao W, Kahouli I, Prakash S. Effect of probiotics *Lactobacillus* and *Bifidobacterium* on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. *J Microbiol Biotechnol*. 2013 Apr;23(4):518-26. DOI: 10.4014/jmb.1205.05018. PMID: 23568206.
14. Moludi, J., Kafil, H.S., Qaisar, S.A. et al. Effect of probiotic supplementation along with calorie restriction on metabolic endotoxemia, and inflammation markers in coronary artery disease patients: a double blind placebo controlled randomized clinical trial. *Nutr J* 20, 47 (2021). DOI : <https://doi.org/10.1186/s12937-021-00703-7>.
15. Petrella C, Strimpakos G, Torcinaro A, Middei S, Ricci V, Gargari G, Mora D, De Santa F, Farioli-Vecchioli S. Proneurogenic and neuroprotective effect of a multi strain probiotic mixture in a mouse model of acute inflammation: Involvement of the gut-brain axis. *Pharmacol Res*. 2021 Oct;172:105795. DOI:10.1016/j.phrs.2021.105795. Epub 2021 Jul 31. Erratum in: *Pharmacol Res*. 2021 Nov;173:105925. PMID: 34339837.
16. Mohammad S, Thiemermann C. Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions. *Front Immunol*. 2021 Jan 11;11:594150. DOI: 10.3389/fimmu.2020.594150. PMID: 33505393; PMCID: PMC7829348.
17. Cristofori F, Dargenio VN, Dargenio C, Miniello VL, Barone M, Francavilla R. Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body. *Front Immunol*. 2021 Feb 26;12:578386. DOI: 10.3389/fimmu.2021.578386. PMID: 33717063; PMCID: PMC7953067.
18. Hutchinson, Ashley N et al. "The Potential Effects of Probiotics and ω -3 Fatty Acids on Chronic Low-Grade Inflammation." *Nutrients* vol. 12,8 2402. 11 Aug. 2020, DOI:10.3390/nu12082402
19. Abrahamsson TR, Jakobsson T, Björkstén B, Oldaeus G, Jenmalm MC. No effect of probiotics on respiratory allergies: a seven-year follow-up of a randomized controlled trial in infancy. *Pediatr Allergy Immunol*. 2013 Sep;24(6):556-61. DOI: 10.1111/pai.12104. Epub 2013 Jul 31. PMID: 23902407.
20. Kekkonen RA, Vasankari TJ, Vuorimaa T, Hahtela T, Julkunen I, Korpela R. The effect of probiotics on respiratory infections and gastrointestinal symptoms during training in marathon runners. *Int J Sport Nutr Exerc Metab*. 2007 Aug;17(4):352-63. DOI: 10.1123/ijsnem.17.4.352. PMID: 17962710.
21. Wang, Yizhong PhDa,*; Li, Xiaolu MDa; Ge, Ting MDa; Xiao, Yongmei MDa; Liao, Yang MDa; Cui, Yun MDb; Zhang, Yucai MD, PhD; Ho, Wenzhe MD, MPHc; Yu,

- Guangjun PhdD,*; Zhang, Ting MD, PhDa,* Probiotics for prevention and treatment of respiratory tract infections in children, *Medicine*: August 2016 - Volume 95 - Issue 31 - p e4509 DOI: 10.1097/MD.0000000000004509
22. Agamennone V, Krul CAM, Rijkers G, Kort R. A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands. *BMC Gastroenterol*. 2018 Aug 6;18(1):103. DOI: 10.1186/s12876-018-0831-x. PMID: 30078376; PMCID: PMC6091175.
 23. Zawistowska-Rojek A, Tyski S. Are Probiotic Really Safe for Humans? *Pol J Microbiol*. 2018;67(3):251-258. DOI: 10.21307/pjm-2018-044. PMID: 30451441; PMCID: PMC7256845.
 24. Orlandoni P, Jukic Peladic N, Amoruso A, Pane M, Di Rosa M, Vedruccio J, Santini F. Safety and Efficacy of Probiotic Supplementation in Reducing the Incidence of Infections and Modulating Inflammation in the Elderly with Feeding Tubes: A Pilot, Double-Blind, Placebo-Controlled Study, "IntegPRO". *Nutrients*. 2021 Jan 27;13(2):391. DOI: 10.3390/nu13020391. PMID: 33513820; PMCID: PMC7911800.
 25. Tremblay A, Xu X, Colee J, Tompkins TA. Efficacy of a Multi-Strain Probiotic Formulation in Pediatric Populations: A Comprehensive Review of Clinical Studies. *Nutrients*. 2021 Jun 1;13(6):1908. DOI: 10.3390/nu13061908. PMID: 34206098; PMCID: PMC8226750.
 26. Morrow LE, Gogineni V, Malesker MA. Probiotic, prebiotic, and synbiotic use in critically ill patients. *Curr Opin Crit Care*. 2012 Apr;18(2):186-91. DOI:10.1097/MCC.0b013e3283514b17. PMID: 22343306.
 27. Van den Nieuwboer M, Claassen E, Morelli L, Guarner F, Brummer RJ. Probiotic and synbiotic safety in infants under two years of age. *Benef Microbes*. 2014 Mar;5(1):45-60. DOI: 10.3920/BM2013.0046. PMID: 24463207.
 28. Van den Nieuwboer M, Brummer RJ, Guarner F, Morelli L, Cabana M, Claassen E. Safety of probiotics and synbiotics in children under 18 years of age. *Benef Microbes*. 2015;6(5):615-30. DOI: 10.3920/BM2014.0157. Epub 2015 Apr 22. PMID: 25809217.
 29. Van den Nieuwboer M, Brummer RJ, Guarner F, Morelli L, Cabana M, Claassen E. The administration of probiotics and synbiotics in immune compromised adults: is it safe? *Benef Microbes*. 2015 Mar;6(1):3-17. DOI: 10.3920/BM2014.0079. PMID: 25304690.
 30. Centers for Disease Control and Prevention (US); National Center for Chronic Disease Prevention and Health Promotion (US); Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2010. 4, Nicotine Addiction: Past and Present. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK53018/>
 31. https://www.cdc.gov/tobacco/data_statistics/fact_sheets/tobacco_industry/hooks/index.htm
 32. Shannon Tushingam, Charles M. Snyder, Korey J. Brownstein, William J. Damitio, David R. Gang, Biomolecular archaeology reveals ancient origins of indigenous tobacco smoking in North American Plateau, *Proceedings of the National Academy of Sciences* Nov 2018, 115 (46) 11742- 11747; DOI: 10.1073/pnas.1813796115
 33. Damitio W (2018) Pipes and smoking in precontact Pacific Northwest societies. Master's thesis (Washington State University, Pullman, WA).
 34. Harder DA (1998) A synthetic overview of the Tucannon phase in the lower Snake River region of Washington and Idaho. Master's thesis (Washington State University, Pullman, WA).
 35. Galm JR, Komen D (2012) Cox's Pond and Middle Holocene ceremonial activity in the Inland Pacific Northwest. *Festschrift in Honor of Max G. Pavesic*, eds Reid KC, Galm JR (Northwest Anthropology, Richland, WA).
 36. Mishra, Shanu, and M B Mishra. "Tobacco: Its historical, cultural, oral, and periodontal health association." *Journal of International Society of Preventive & Community Dentistry* vol. 3,1 (2013): 12-8. DOI:10.4103/2231-0762.115708
 37. Goodman J. Abingdon: Routledge; 1994. Tobacco in history: The Cultures of dependence.
 38. Duke, D., Wohlgemuth, E., Adams, K.R. et al. Earliest evidence for human use of tobacco in the Pleistocene Americas. *Nat Hum Behav* (2021). <https://doi.org/10.1038/s41562-021-01202-9>
 39. Davis LG, Madsen DB, Becerra-Valdivia L, Higham T, Sisson DA, Skinner SM, Stueber D, Nyers AJ, Keen-Zebert A, Neudorf C, Cheyney M, Izuho M, Iizuka F, Burns SR, Epps CW, Willis SC, Buvit I. Late Upper Paleolithic occupation at Cooper's Ferry, Idaho, USA, ~16,000 years ago. *Science*. 2019 Aug 30;365(6456):891-897. DOI: 10.1126/science.aax9830. PMID: 31467216.
 40. Waters MR. Late Pleistocene exploration and settlement of the Americas by modern humans. *Science*. 2019 Jul 12;365(6449):eaat5447. DOI: 10.1126/science.aat5447. PMID: 31296740.
 41. Smith, Elizabeth A, and Ruth E Malone. "“Everywhere the soldier will be”: wartime tobacco promotion in the US military." *American journal of public health* vol. 99,9 (2009): 1595-602. DOI:10.2105/AJPH.2008.152983
 42. Smith EA, Malone RE. Tobacco promotion to military personnel: "the plums are here to be plucked". *Mil Med*. 2009 Aug;174(8):797-806. DOI:10.7205/milmed-d-04-4108. PMID:19743733; PMCID: PMC2794239.
 43. Joseph AM, Muggli M, Pearson KC, Lando H. The cigarette manufacturers' efforts to promote tobacco to the U.S. military. *Mil Med*. 2005 Oct;170(10):874-80. DOI: 10.7205/milmed.170.10.874. PMID: 16435763.
 44. Piret, Jocelyne, and Guy Boivin. "Pandemics Throughout History." *Frontiers in microbiology* vol. 11 631736. 15 Jan. 2021, DOI :10.3389/fmicb.2020.631736a

45. Byerly, Carol R. "The U.S. military and the influenza pandemic of 1918-1919." *Public health reports* (Washington, D.C. : 1974) vol. 125 Suppl 3, Suppl 3 (2010): 82-91.
46. Wever PC, van Bergen L. Death from 1918 pandemic influenza during the First World War: a perspective from personal and anecdotal evidence. *Influenza Other Respir Viruses*. 2014 Sep;8(5):538-46. DOI: 10.1111/irv.12267. Epub 2014 Jun 27. PMID: 24975798; PMCID: PMC4181817.
47. Wilson N, Summers J, Baker M, Rice G. A bizarre case of drowning as a result of pandemic influenza (1918 pandemic). *N Z Med J*. 2009 Sep 11;122(1302):92-4. PMID: 19834526.
48. Gábor K. Spanyolnáthajárvány a Monarchiában 1918 oszén a katonai források tükrében [Spanish influenza epidemic in the Austro-Hungarian Monarchy in the fall of 1918--as reflected in military sources]. *Orv Hetil*. 2006 May 7;147(18):850-1. Hungarian. PMID: 16784141.
49. Økland H, Mamelund SE. Race and 1918 Influenza Pandemic in the United States: A Review of the Literature. *Int J Environ Res Public Health*. 2019 Jul 12;16(14):2487. DOI: 10.3390/ijerph16142487. PMID: 31336864; PMCID: PMC6678782.
50. Kilbourne, Edwin D. "Influenza pandemics of the 20th century." *Emerging infectious diseases* vol. 12,1 (2006): 9-14. DOI:10.3201/eid1201.051254
51. Silvia Racedo, Julio Villena, Susana Salva & Susana Alvarez (2009) Influence of yogurt consumption on the respiratory immune response, *Food and Agricultural Immunology*, 20:3, 231-244, DOI: 10.1080/09540100903061659
52. Simin Nikbin Meydani, Woel-Kyu Ha, Immunologic effects of yogurt, *The American Journal of Clinical Nutrition*, Volume 71, Issue 4, April 2000, Pages 861–872, <https://doi.org/10.1093/ajcn/71.4.861>
53. Benjamin H. Mullish, Julian R. Marchesi, Julie A.K. McDonald, Daniel A. Pass, Giulia Masetti, Daryn R. Michael, Sue Plummer, Alison A. Jack, Thomas S. Davies, Timothy R. Hughes & Duolao Wang (2021) Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?, *Gut Microbes*, 13:1, DOI: 10.1080/19490976.2021.1900997
54. Britti, Maria & Roselli, Marianna & Finamore, Alberto & Merendino, Nicolò & Mengheri, Elena. (2006). Regulation of immune response at intestinal and peripheral sites by probiotics. *Biologia*. 61. 735-740. 10.2478/s11756-006-0150-5.
55. Chew, Sweelin & Kolosowska, Natalia & Saveleva, Liudmila & Malm, Tarja & Kanninen, Katja. (2020). Impairment of mitochondrial function by particulate matter: Implications for the brain. *Neurochemistry International*. 135. 104694. 10.1016/j.neuint.2020.104694.
56. Qiu, Feifei et al. "Impacts of cigarette smoking on immune responsiveness: Up and down or upside down?." *Oncotarget* vol. 8,1 (2017): 268-284. DOI:10.18632/oncotarget.13613
57. Galdeano, C Maldonado, and G Perdigon. "The probiotic bacterium *Lactobacillus casei* induces activation of the gut mucosal immune system through innate immunity." *Clinical and vaccine immunology : CVI* vol. 13,2 (2006): 219-26. DOI:10.1128/CVI.13.2.219-226.2006.
58. Doron S, Snyderman DR. Risk and safety of probiotics. *Clin Infect Dis*. 2015 May 15;60 Suppl 2(Suppl 2):S129-34. DOI: 10.1093/cid/civ085. PMID: 25922398; PMCID: PMC4490230.
59. Kothari D, Patel S, Kim SK. Probiotic supplements might not be universally-effective and safe: A review. *Biomed Pharmacother*. 2019 Mar;111:537-547. DOI: 10.1016/j.biopha.2018.12.104. Epub 2018 Dec 28. PMID: 30597307.
60. Racedo, Silvia María, et al. *Lactobacillus Casei Administration Reduces Lung Injuries in a Streptococcus Pneumoniae Infection in Mice*. 2006.
61. Mortaz E, Adcock IM, Folkerts G, Barnes PJ, Paul Vos A, Garssen J. Probiotics in the management of lung diseases. *Mediators Inflamm*. 2013;2013:751068. DOI: 10.1155/2013/751068. Epub 2013 May 8. PMID: 23737654; PMCID: PMC3662166.
62. Reyes, Pedro & González-Vázquez, Raquel & Torres Maravilla, Edgar & Tello, Mario & Bermúdez-Humarán, Luis & Mayorga, Lino. (2021). Probiotics against Viral Infections: Current Clinical Trials and Future Perspectives. *Immuno*. 1. 468-498. 10.3390/immuno1040034.
63. Eguchi, K., Fujitani, N., Nakagawa, H. et al. Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium *Lactobacillus gasseri* SBT2055. *Sci Rep* 9, 4812 (2019). <https://doi.org/10.1038/s41598-019-39602-7>
64. Baud, David & Agri, Varvara & Gibson, Glenn & Reid, Gregor & Giannoni, Eric. (2020). Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic. *Frontiers in Public Health*. 8. 186. 10.3389/fpubh.2020.00186.
65. Mansour Mohamadzadeh, Scott Olson, Warren V. Kalina, Gordon Ruthel, Gretchen L. Demmin, Kelly L. Warfield, Sina Bavari, Todd R. Klaenhammer, *Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization*, *Proceedings of the National Academy of Sciences* Feb 2005, 102 (8) 2880-2885; DOI: 10.1073/pnas.0500098102.
66. Baghbani T, Nikzad H, Azadbakht J, Izadpanah F, Haddad Kashani H. Dual and mutual interaction between microbiota and viral infections: a possible treat for COVID-19. *Microb Cell Fact*. 2020 Nov 26;19(1):217. DOI: 10.1186/s12934-020-01483-1. PMID: 33243230; PMCID: PMC7689646.
67. Lehtoranta L, Latvala S, Lehtinen MJ. Role of Probiotics in Stimulating the Immune System in Viral Respiratory Tract Infections: A Narrative Review. *Nutrients*. 2020 Oct 16;12(10):3163. DOI: 10.3390/nu12103163. PMID: 33081138; PMCID: PMC7602805.
68. American Lung Association. *Hookah Smoking: A Growing Threat to Public Health*. 2011.
69. American Lung Association. *An Emerging Deadly Trend: Waterpipe Tobacco Use*. February 2007.
70. Johnston DL, Miech RA, O'Malley PM et al. *Monitoring the Future National Survey Results on Drug Use 1975-*

- 2018: Overview of Key Findings on Adolescents Drug Use. external icon Ann Arbor: Institute for Social Research, University of Michigan, 2019. <http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2018.pdf>
71. Shulenberg JE, Johnston DL, O'Malley PM et al. Monitoring the Future National Survey on Drug Use 1975-2018: Volume II, College Students and Adults Ages 19–60. external icon Ann Arbor: Institute for Social Research, The University of Michigan, 2019 http://www.monitoringthefuture.org/pubs/monographs/mtf-vol2_2018.pdf
 72. U.S. Department of Health and Human Services. Preventing Tobacco Use Among Youth and Young Adults: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Office on Smoking and Health, 2012 https://www.cdc.gov/tobacco/data_statistics/sgr/2012/index.htm
 73. U.S. Department of Health and Human Services. E-Cigarette Use Among Youth and Young Adults. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2016 https://www.cdc.gov/tobacco/data_statistics/sgr/e-cigarettes/index.htm
 74. National Academies of Sciences, Engineering, and Medicine. Public Health Consequences of E- Cigarettes. external icon Washington, DC: The National Academies Press, 2018 <https://www.nap.edu/catalog/24952/public-health-consequences-of-e-cigarettes>
 75. Iman A. Nuwayhid, Bassem Yamout, Ghassan Azar, Mona Al Kouatly Kambris, Narghile (Hubble- Bubble) Smoking, Low Birth Weight, and Other Pregnancy Outcomes, American Journal of Epidemiology, Volume 148, Issue 4, 15 August 1998, Pages 375–383, <https://doi.org/10.1093/oxfordjournals.aje.a009656>
 76. World Health Organization. Tobacco Regulation Advisory Note. Waterpipe Tobacco Smoking: Health Effects, Research Needs and Recommended Actions by Regulators external icon. Geneva (Switzerland): World Health Organization, Tobacco Free Initiative, 2005
 77. Stadlbauer, Vanessa. (2015). Immunosuppression and probiotics: Are they effective and safe?. Beneficial microbes. 6. 1-6. 10.3920/BM2015.0065.
 78. S. P. Borriello, W. P Hammes, W. Holzapfel, P. Marteau, J. Schrezenmeir, M. Vaara, V. Valtonen, Safety of Probiotics That Contain Lactobacilli or Bifidobacteria, Clinical Infectious Diseases, Volume 36, Issue 6, 15 March 2003, Pages 775–780, <https://doi.org/10.1086/368080>
 79. Stadlbauer V. Immunosuppression and probiotics: are they effective and safe? Benef Microbes. 2015;6(6):823-8. DOI: 10.3920/BM2015.0065. Epub 2015 Aug 19. PMID: 26287986.
 80. Lerner A, Shoenfeld Y, Matthias T. Probiotics: If It Does Not Help It Does Not Do Any Harm. Really? Microorganisms. 2019 Apr 11;7(4):104. doi: 10.3390/microorganisms7040104. PMID: 30979072; PMCID: PMC6517882.
 81. Happel AU, Barnabas SL, Froissart R, Passmore JS. Weighing in on the risks and benefits of probiotic use in HIV-infected and immunocompromised populations. Benef Microbes. 2018 Feb 27;9(2):239-246. DOI: 10.3920/BM2017.0106. Epub 2018 Jan 18. PMID: 29345159.
 82. Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M. A systematic review of the safety of probiotics. Expert Opin Drug Saf. 2014 Feb;13(2):227-39. DOI: 10.1517/14740338.2014.872627. Epub 2014 Jan 3. PMID: 24405164.
 83. Piqué, Núria et al. “Health Benefits of Heat-Killed (Tyndallized) Probiotics: An Overview.” International journal of molecular sciences vol. 20,10 2534. 23 May. 2019, DOI:10.3390/ijms20102534
 84. Martinelli M, Ummarino D, Giugliano FP, Sciorio E, Tortora C, Bruzzese D, De Giovanni D, Rutigliano I, Valenti S, Romano C, Campanozzi A, Miele E, Staiano A. Efficacy of a standardized extract of *Matricariae chamomilla* L., *Melissa officinalis* L. and tyndallized *Lactobacillus acidophilus* (HA122) in infantile colic: An open randomized controlled trial. Neurogastroenterol Motil. 2017 Dec;29(12). DOI: 10.1111/nmo.13145. Epub 2017 Jun 30. PMID: 28665038.
 85. Chen, MF., Weng, KF., Huang, SY. et al. Pretreatment with a heat-killed probiotic modulates monocyte chemoattractant protein-1 and reduces the pathogenicity of influenza and enterovirus 71 infections. Mucosal Immunol 10, 215–227 (2017). <https://doi.org/10.1038/mi.2016.31>
 86. Ashraf R, Shah NP. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr. 2014;54(7):938-56. DOI:10.1080/10408398.2011.619671. PMID: 24499072.
 87. Maldonado Galdeano C, Cazorla SI, Lemme Dumit JM, Vélez E, Perdígón G. Beneficial Effects of Probiotic Consumption on the Immune System. Ann Nutr Metab. 2019;74(2):115-124. DOI : 10.1159/000496426. Epub 2019 Jan 23. PMID: 30673668.
 88. Ho YH, Lu YC, Chang HC, Lee SY, Tsai MF, Huang YT, Hsu TY. Daily intake of probiotics with high IFN- γ /IL-10 ratio increases the cytotoxicity of human natural killer cells: a personalized probiotic approach. J Immunol Res. 2014;2014:721505. DOI : 10.1155/2014/721505. Epub 2014 Dec 11. PMID: 25759833; PMCID: PMC4352450.
 89. Sundararaman, A., Ray, M., Ravindra, P.V. et al. Role of probiotics to combat viral infections with emphasis on COVID-19. Appl Microbiol Biotechnol 104, 8089–8104 (2020). <https://doi.org/10.1007/s00253-020-10832-4>
 90. Jorge Gutierrez-Merino, Beatriz Isla, Theo Combes, Fernando Martinez-Estrada & Carlos Maluquer De Motes (2020) Beneficial bacteria activate type-I interferon production via the intracellular cytosolic sensors STING and MAVS, Gut Microbes, 11:4, 771–788, DOI: 10.1080/19490976.2019.1707015
 91. Olaimat, A.N., Aolymat, I., Al-Holy, M. et al. The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. npj Sci Food 4, 17 (2020). <https://doi.org/10.1038/s41538-020-00078-9>

92. Jeon SG, Kayama H, Ueda Y, Takahashi T, Asahara T, Tsuji H, Tsuji NM, Kiyono H, Ma JS, Kusu T, Okumura R, Hara H, Yoshida H, Yamamoto M, Nomoto K, Takeda K. Probiotic *Bifidobacterium breve* induces IL-10-producing Tr1 cells in the colon. *PLoS Pathog.* 2012;8(5):e1002714. DOI: 10.1371/journal.ppat.1002714. Epub 2012 May 31. PMID: 22693446; PMCID: PMC3364948.
93. De Moreno de Leblanc, Alejandra et al. "Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases." *ISRN gastroenterology* vol. 2011 (2011): 892971. DOI:10.5402/2011/892971
94. Shi HY, Zhu X, Li WL, Mak JWY, Wong SH, Zhu ST, Guo SL, Chan FKL, Zhang ST, Ng SC. Modulation of gut microbiota protects against viral respiratory tract infections: a systematic review of animal and clinical studies. *Eur J Nutr.* 2021 Apr 14:1–24. DOI: 10.1007/s00394-021-02519-x. Epub ahead of print. PMID: 33852069; PMCID: PMC8044287.
95. Wu S, Jiang ZY, Sun YF, Yu B, Chen J, Dai CQ, Wu XL, Tang XL, Chen XY. Microbiota regulates the TLR7 signaling pathway against respiratory tract influenza A virus infection. *Curr Microbiol.* 2013 Oct;67(4):414-22. DOI: 10.1007/s00284-013-0380-z. Epub 2013 May 16. PMID: 23677145
96. Kelly SA, Nzakizwanayo J, Rodgers AM, Zhao L, Weiser R, Tekko IA, McCarthy HO, Ingram RJ, Jones BV, Donnelly RF, Gilmore BF. Antibiotic Therapy and the Gut Microbiome: Investigating the Effect of Delivery Route on Gut Pathogens. *ACS Infect Dis.* 2021 May 14;7(5):1283-1296. DOI: 10.1021/acsinfecdis.1c00081. Epub 2021 Apr 12. PMID: 33843198.
97. Grayson MH, Camarda LE, Hussain SA, Zemple SJ, Hayward M, Lam V, Hunter DA, Santoro JL, Rohlfing M, Cheung DS, Salzman NH. Intestinal Microbiota Disruption Reduces Regulatory T Cells and Increases Respiratory Viral Infection Mortality Through Increased IFN γ Production. *Front Immunol.* 2018 Jul 10;9:1587. DOI: 10.3389/fimmu.2018.01587. PMID: 30042764; PMCID: PMC6048222
98. Abt MC, Osborne LC, Monticelli LA, Doering TA, Alenghat T, Sonnenberg GF, Paley MA, Antenus M, Williams KL, Erikson J, Wherry EJ, Artis D. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. *Immunity.* 2012 Jul 27;37(1):158-70. DOI: 10.1016/j.immuni.2012.04.011. Epub 2012 Jun 14. PMID: 22705104; PMCID: PMC3679670
99. Bradley KC, Finsterbusch K, Schnepf D, Crotta S, Llorian M, Davidson S, Fuchs SY, Staeheli P, Wack A. Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from Influenza Virus Infection. *Cell Rep.* 2019 Jul 2;28(1):245-256.e4. DOI: 10.1016/j.celrep.2019.05.105. PMID: 31269444
100. Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, Iwasaki A. Microbiota regulates immune defense against respiratory tract influenza A virus infection. *Proc Natl Acad Sci U S A.* 2011 Mar 29;108(13):5354-9. DOI: 10.1073/pnas.1019378108. Epub 2011 Mar 14. PMID: 21402903; PMCID: PMC3069176.
101. Gustine JN, Jones D. Immunopathology of Hyperinflammation in COVID-19. *Am J Pathol.* 2021 Jan;191(1):4-17. DOI: 10.1016/j.ajpath.2020.08.009. Epub 2020 Sep 11. PMID: 32919977; PMCID: PMC7484812.
102. Mishra KP, Singh AK, Singh SB. Hyperinflammation and Immune Response Generation in COVID-19. *Neuroimmunomodulation.* 2020;27(2):80-86. DOI: 10.1159/000513198. Epub 2020 Dec 18. PMID: 33341814; PMCID: PMC7801965.
103. Wong RSY. Inflammation in COVID-19: from pathogenesis to treatment. *Int J Clin Exp Pathol.* 2021 Jul 15;14(7):831-844. PMID: 34367415; PMCID: PMC8339720.
104. Tay, M.Z., Poh, C.M., Rénia, L. et al. The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol* 20, 363–374 (2020). <https://doi.org/10.1038/s41577-020-0311-8>.
105. Jordan SC. Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses. *Clin Exp Immunol.* 2021 Jun;204(3):310-320. DOI: 10.1111/cei.13582. Epub 2021 Mar 4. PMID: 33534923; PMCID: PMC8013613.
106. Ni L, Cheng ML, Feng Y, Zhao H, Liu J, Ye F, Ye Q, Zhu G, Li X, Wang P, Shao J, Deng YQ, Wei P, Chen F, Qin CF, Wang G, Li F, Zeng H, Dong C. Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 Patients. *Front Immunol.* 2021 Feb 2;12:603563. DOI: 10.3389/fimmu.2021.603563. PMID: 33603759; PMCID: PMC7884325.
107. Ragab D, Salah Eldin H, Tacimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. *Front Immunol.* 2020 Jun 16;11:1446. DOI: 10.3389/fimmu.2020.01446. PMID: 32612617; PMCID: PMC7308649.
108. Catanzaro, M., Fagiani, F., Racchi, M. et al. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. *Sig Transduct Target Ther* 5, 84 (2020). <https://doi.org/10.1038/s41392-020-0191-1>.
109. Peddapalli A, Gehani M, Kalle AM, Peddapalli SR, Peter AE, Sharad S. Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF- κ B: A Systematic Review. *Viruses.* 2021 Feb 27;13(3):378. DOI: 10.3390/v13030378. PMID: 33673529; PMCID: PMC7997247.
110. Lucas, C., Klein, J., Sundaram, M.E. et al. Delayed production of neutralizing antibodies correlates with fatal COVID-19. *Nat Med* 27, 1178–1186 (2021). <https://doi.org/10.1038/s41591-021-01355-0>
111. Wu, J., Liang, B., Chen, C. et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. *Nat Commun* 12, 1813 (2021). <https://doi.org/10.1038/s41467-021-22034-1>
112. Hasan A, Al-Ozairi E, Al-Baqsumi Z, Ahmad R, Al-Mulla F. Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. *Immunotargets Ther.* 2021;10:63- 85, <https://doi.org/10.2147/ITT.S280706>

113. Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral Responses and Serological Assays in SARS-CoV-2 Infections. *Front Immunol*. 2020 Dec 18;11:610688. DOI: 10.3389/fimmu.2020.610688. PMID: 33391281; PMCID: PMC7775512.
114. Thalia et al. Timeline analysis of IgA and IgG levels in Covid-19 hospitalized patients according to the clinical outcome. *Jornal Brasileiro de Patologia e Medicina Laboratorial* [online]. 2021, v. 57 [Accessed 23 August 2021], e4022021. DOI: <https://doi.org/10.5935/1676-2444.20210021>. Epub 09 July 2021. ISSN 1678-4774.
115. Fraser DD, Cepinskas G, Slessarev M, Martin CM, Daley M, Patel MA, Miller MR, Patterson EK, O’Gorman DB, Gill SE, Higgins I, John JPP, Melo C, Nini L, Wang X, Zeidler J, Cruz-Aguado JA. Critically Ill COVID-19 Patients Exhibit Anti-SARS-CoV-2 Serological Responses. *Pathophysiology*. 2021; 28(2):212-223. <https://doi.org/10.3390/pathophysiology2802001>
116. Jafari, D. et al. (2021). Trajectories of Hypoxemia & Respiratory System Mechanics of COVID-19 ARDS in the NorthCARDS dataset. medRxiv. <https://doi.org/10.1101/2021.01.26.21250492>, <https://www.medrxiv.org/content/10.1101/2021.01.26.21250492v1>
117. Nitsure, Mohana et al. “Mechanisms of Hypoxia in COVID-19 Patients: A Pathophysiologic Reflection.” *Indian journal of critical care medicine* : peer-reviewed, official publication of Indian Society of Critical Care Medicine vol. 24,10 (2020): 967-970. DOI :10.5005/jp-journals-10071- 23547
118. Li, X., Ma, X. Acute respiratory failure in COVID-19: is it “typical” ARDS?. *Crit Care* 24, 198 (2020). <https://doi.org/10.1186/s13054-020-02911-9>
119. Swenson KE, Ruoss SJ, Swenson ER. The Pathophysiology and Dangers of Silent Hypoxemia in COVID-19 Lung Injury. *Ann Am Thorac Soc*. 2021 Jul;18(7):1098-1105. DOI : 10.1513/AnnalsATS.202011-1376CME. PMID: 33621159; PMCID: PMC8328372.
120. Messina E, Danise A, Ferrari G, Andolina A, Chiurlo M, Razanakolona M, Barakat M, Israel RJ, Castagna A. Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series. *Infect Dis Ther*. 2021 Jul 23:1–14. DOI : 10.1007/s40121-021-00493-9. Epub ahead of print. PMID: 34302258; PMCID: PMC8302211.
121. Archer SL, Sharp WW, Weir EK. Differentiating COVID-19 Pneumonia From Acute Respiratory Distress Syndrome and High Altitude Pulmonary Edema: Therapeutic Implications. *Circulation*. 2020 Jul 14;142(2):101-104. DOI : 10.1161/CIRCULATIONAHA.120.047915. Epub 2020 May 5. PMID: 32369390; PMCID: PMC7363563.
122. Zhou C, Gao C, Xie Y, Xu M. COVID-19 with spontaneous pneumomediastinum. *Lancet Infect Dis*. 2020 Apr;20(4):510. doi: 10.1016/S1473-3099(20)30156-0. Epub 2020 Mar 9. PMID: 32164830; PMCID: PMC7128610
123. Gallelli, Luca et al. “Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.” *Journal of clinical pharmacology* vol. 60,7 (2020): 815-825. DOI:10.1002/jcph.1644
124. Leng, L., Cao, R., Ma, J. et al. Pathological features of COVID-19-associated lung injury: a preliminary proteomics report based on clinical samples. *Sig Transduct Target Ther* 5, 240 (2020). <https://doi.org/10.1038/s41392-020-00355-9>
125. Borczuk, A.C., Salvatore, S.P., Seshan, S.V. et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. *Mod Pathol* 33, 2156–2168 (2020). <https://doi.org/10.1038/s41379-020-00661-1>
126. Mauad, T., Duarte-Neto, A.N., da Silva, L.F.F. et al. Tracking the time course of pathological patterns of lung injury in severe COVID-19. *Respir Res* 22, 32 (2021). <https://doi.org/10.1186/s12931-021-01628-9>
127. Weaver, L., Das, A., Saffaran, S. et al. High risk of patient self-inflicted lung injury in COVID-19 with frequently encountered spontaneous breathing patterns: a computational modelling study. *Ann. Intensive Care* 11, 109 (2021). <https://doi.org/10.1186/s13613-021-00904-7>
128. Fajnzylber, J., Regan, J., Coxen, K. et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. *Nat Commun* 11, 5493 (2020). <https://doi.org/10.1038/s41467-020-19057-5>
129. Argyropoulos KV, Serrano A, Hu J, Black M, Feng X, Shen G, Call M, Kim MJ, Lytle A, Belovarac B, Vougiouklakis T, Lin LH, Moran U, Heguy A, Troxel A, Snuderl M, Osman I, Cotzia P, Jour G. Association of Initial Viral Load in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients with Outcome and Symptoms. *Am J Pathol*. 2020 Sep;190(9):1881-1887. DOI : 10.1016/j.ajpath.2020.07.001. Epub 2020 Jul 3. PMID: 32628931; PMCID: PMC7332909.
130. Manuel A. Torres Acosta, Benjamin D. Singer, Pathogenesis of COVID-19-induced ARDS: implications for an aging population, *European Respiratory Journal* Jan 2020, 2002049; DOI: 10.1183/13993003.02049-2020
131. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January–March 2020: retrospective cohort study *BMJ* 2020; 369 :m1443 DOI:10.1136/bmj.m1443
132. Pujadas E, Chaudhry F, McBride R, Richter F, Zhao S, Wajnberg A, Nadkarni G, Glicksberg BS, Houldsworth J, Cordon-Cardo C. SARS-CoV-2 viral load predicts COVID-19 mortality. *Lancet Respir Med*. 2020 Sep;8(9):e70. DOI: 10.1016/S2213-2600(20)30354-4. Epub 2020 Aug 6. PMID: 32771081; PMCID: PMC7836878.
133. Gallelli, Luca et al. “Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.” *Journal of clinical pharmacology* vol. 60,7 (2020): 815-825. DOI:10.1002/jcph.1644

Copyright: ©2023 Bose Karthik. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.